Evidence map›Paper›PMID 41263849›Full record

ArticleBMJ open2025

Individualised dosimetry for holmium-166 RE in patients with unresectable hepatocellular carcinoma; a multi-centre, interventional, non-randomised, non-comparative, open label, phase II study: RHEPaiR.

Maria Qurashi, Maria Martinez, Caroline Ward, Charlotte Wyard, Hooshang Izadi, Chloe Bowen, Sairah R Khan, Paul Tait, Maarten Smits, Joep de Bruijne and 3 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06302400 (Individualized Dosimetry for Holmium-166 Radioembolization in Patients With Unresectable Hepatocellular Carcinoma; a Multi-centre, Interventional, Non-randomized, Non-comparative, Open Label, Early Phase II Study), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06302400 naterminatednot on this map

Individualized Dosimetry for Holmium-166 Radioembolization in Patients With Unresectable Hepatocellular Carcinoma; a Multi-centre, Interventional, Non-randomized, Non-comparative, Open Label, Early Phase II Study

TypeinterventionalSponsorImperial College LondonRan2024 to 2025Enrolled4ConditionsCarcinoma, HepatocellularArms166Holmium microspheres (QuiremSpheres®)
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Maria QurashiImperial College London, London, UK.
Maria MartinezImperial College London, London, UK.
Caroline WardDepartment of Surgery and Cancer, Hammersmith Hospital, London, UK.
Charlotte WyardImperial College London, London, UK.
Hooshang IzadiDepartment of Mechanical Engineering and Mathematical Sciences, Oxford Brookes University, Oxford, Oxfordshire, UK.
Chloe BowenDepartment of Nuclear Medicine, Hammersmith Hospital, London, UK.
Sairah R KhanDepartment of Nuclear Medicine, Hammersmith Hospital, London, UK.
Paul TaitDepartment of Interventional Radiology, Hammersmith Hospital, London, UK.
Maarten SmitsDepartment of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, Netherlands.
Joep de BruijneDepartment of Hepatology, University Medical Center Utrecht, Utrecht, Netherlands.
Robert ThomasUniversity College London Hospitals NHS Foundation Trust, London, UK.
Marnix G E H LamNuclear medicine, Universitair Medisch Centrum Utrecht, Utrecht, Utrecht, Netherlands.
Rohini SharmaDepartment of Interventional Radiology, Hammersmith Hospital, London, UK r.sharma@imperial.ac.uk.ORCID http://orcid.org/0000-0003-2441-549X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRadioembolisation (RE) is gaining traction as a robust treatment option for patients with hepatocellular cancer (HCC) across all cancer stages. RE allows the delivery of targeted high-dose radiation directly to tumours, with relative sparing of the surrounding liver tissue. Traditionally, radiation has been delivered using METHODS AND ANALYSIS: 15 eligible participants will be recruited to receive [ ETHICS AND DISSEMINATION: The study has received approval from the East Midlands-Nottingham 1 Research Ethics Committee-approval number 23/EM/0239. The study will be performed in compliance with the Declaration of Helsinki and the principles of Good Clinical Practice. Signed informed consent will be obtained from each patient before study entry. The results will be disseminated through publication in a peer-reviewed scientific journal. TRIAL REGISTRATION NUMBER: Clinicaltrials.gov NCT06302400.

Indexed as

Carcinoma, HepatocellularEmbolization, TherapeuticHolmiumLiver NeoplasmsRadioisotopesRadiopharmaceuticalsClinical Trials, Phase II as TopicFemaleHumansMaleMicrospheresMulticenter Studies as TopicRadiometryHolmiumHolmium-166RadioisotopesRadiopharmaceuticalsHepatobiliary tumoursInterventional radiologyQuality of LifeSafety

Identifiers

PMID41263849
PMCPMC12636873

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.